Congress demands transparency on drug-plan middlemen's hidden deals
S. 3729 — PBM Reporting Transparency Act · Filed by Mark Warner (D-VA) · 3 cosponsors · Introduced Jan 29, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires Medicare's Payment Advisory Commission (MedPAC) to study and report to Congress on the agreements between pharmacy benefit managers (PBMs) and Medicare drug plans, examining trends, cost impacts on patients, and pharmacy reimbursement rates. The first report is due roughly 2 years after data becomes available; a follow-up report tracking changes is due 2 years later.
Why we flagged it
The bill's sole operative mechanism is a reporting requirement — it does not regulate PBMs, cap fees, or change payment rules. Its function is to illuminate currently opaque agreements so Congress can make informed policy decisions.
What the text implies
- Report findings may trigger follow-on legislation to regulate PBM practices, claw back rebates, or restructure drug-plan contracting — the transparency itself is a precursor to potential enforcement.
- PBMs may alter or obscure agreement terms in anticipation of reporting, or lobby to narrow the scope of data MedPAC can access before the first report deadline.
- Report will likely expose disparities in reimbursement and patient costs across plans and regions, potentially embarrassing high-cost or low-transparency plans and creating political pressure for reform.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Ordinary Medicare beneficiaries and the public gain transparency into PBM practices that directly affect their out-of-pocket drug costs and pharmacy access. Congress obtains data to evaluate whether regulatory or contractual reforms are needed, shifting power from opaque private intermediaries toward democratic oversight.
Named in the bill
Medicare Payment Advisory Commission (MedPAC), Pharmacy Benefit Managers (PBMs), Medicare Prescription Drug Plans (Part D), Medicare Advantage Prescription Drug Plans (MA-PD), U.S. Congress, Secretary of Health and Human Services
Where it stands
3 cosponsors: 2 Republicans, 1 Democrats.
- Jan 29, 2026 — Introduced · Congress.gov: “Introduced in Senate”
- Jan 29, 2026 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (1,297 characters) on Aug 14, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Congress demands transparency on drug-plan middlemen's hidden deals” QuorumCivic. https://share.quorumcivic.app/bill/119/s3729 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.